Switching to Tenofovir Alafenamide after liver transplant for HBV
Part of Digestive system, Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if switching your current hepatitis B antiviral to Tenofovir Alafenamide (TAF) keeps your new liver working well with fewer side effects. It is for people who had a liver transplant due to hepatitis B and have stable liver function for at least a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You had a liver transplant for hepatitis B and your new liver has worked well for at least one year.
- You are currently taking a hepatitis B antiviral other than TAF.
- Your liver blood tests (ALT and AST) are less than 3 times the normal range.
- You are taking tacrolimus and your blood level stays between 3 and 10 ng/mL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This trial tests switching from standard entecavir pills to a different form (ODT, which dissolves in your mouth) for people who have had a stable liver transplant for hepatitis B. It aims to see if the new form works just as well and is safe.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
This trial tests if taking tenofovir alafenamide (TAF) alone works as well as combining it with entecavir (ETV) to improve outcomes for people with hepatitis B and liver cancer who are receiving immunotherapy.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.